Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12272985 | 0.85 | AR (0.33) | MAPTPIM1PIM2 | |
| SCHEMBL3112042 | 0.76 | MAPT (0.36) | MAPTPIM1PIM2NOX1GSK3B | |
| SCHEMBL10590860 | 0.70 | EPHX2 (0.47) | MAPTNOX1MEN1MAPK1KMT2A | |
| Hydromethylthionine SCHEMBL12592446 | 0.70 | SNCA (0.50) | MAPTNOX1MEN1MAPK1KMT2A | |
| Hydromethylthionine SCHEMBL109756 | 0.70 | SNCA (0.50) | MAPTNOX1MEN1MAPK1KMT2A | |
| Hydromethylthionine SCHEMBL29356148 | 0.70 | SNCA (0.50) | MAPTNOX1MEN1MAPK1KMT2A | |
| SCHEMBL12273200 | 0.69 | IDH1 (0.31) | — | |
| Hydromethylthionine SCHEMBL25199191 | 0.69 | SNCA (0.48) | MAPTNOX1MEN1MAPK1KMT2A | |
| Hydromethylthionine SCHEMBL25194477 | 0.69 | SNCA (0.48) | MAPTNOX1MEN1MAPK1KMT2A | |
| Hydromethylthionine SCHEMBL12470963 | 0.69 | SNCA (0.48) | MAPTNOX1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | claimed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | MAPT 1842/4885PIM1 80/4885PIM2 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.